MGNXMacroGenics, Inc.

MGNX Stock Price, Valuation & Chart | MacroGenics, Inc.

Compare

$4.320+0.28 (+6.93%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology MGNX intrinsic value MGNX calculated fair value vs price

Overview Financials Dividends Ratios

MGNX Historical price chart

MGNX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization274.59M

PE Ratio-3.93

EPS-1.1

Trading Volume581.57K

Today's High/Low4.37/4.05

Dividend Yield0.00

52 Week High/Low5.08/1.29

Shares Outstanding63.56M

MGNX Financial Statement

MGNX Analyst ratings

MGNX Analysis & performance metrics

MGNX Company profile

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA…

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast…

MGNX Management team

Name

Position

James KarrelsCFO

Senior Vice President, Chief Financial Officer & Corporate Secretary

Stephen L. Eck M.D., Ph.D.

Senior Vice President of Clinical Development & Chief Medical Officer

Beth Smith

Vice President, Controller & Treasurer

Ezio Bonvini M.D.

Senior Vice President of Research & Chief Scientific Officer

Jeffrey Stuart Peters J.D.

Senior Vice President, General Counsel & Corporate Compliance Officer

Scott Koenig M.D., Ph.D.CEO

President, Chief Executive Officer & Director

Eric Blasius RisserCOO

Chief Operating Officer

Thomas M. Spitznagel Ph.D.

Senior Vice President of Technical Operations

Name

Position

James KarrelsCFO

Senior Vice President, Chief Financial Officer & Corporate Secretary

Stephen L. Eck M.D., Ph.D.

Senior Vice President of Clinical Development & Chief Medical Officer

Beth Smith

Vice President, Controller & Treasurer

Ezio Bonvini M.D.

Senior Vice President of Research & Chief Scientific Officer

Jeffrey Stuart Peters J.D.

Senior Vice President, General Counsel & Corporate Compliance Officer

Scott Koenig M.D., Ph.D.CEO

President, Chief Executive Officer & Director

Eric Blasius RisserCOO

Chief Operating Officer

Thomas M. Spitznagel Ph.D.

Senior Vice President of Technical Operations

Management Team

James KarrelsCFO

Senior Vice President, Chief Financial Officer & Corporate Secretary

Stephen L. Eck M.D., Ph.D.

Senior Vice President of Clinical Development & Chief Medical Officer

Beth Smith

Vice President, Controller & Treasurer

Ezio Bonvini M.D.

Senior Vice President of Research & Chief Scientific Officer

Jeffrey Stuart Peters J.D.

Senior Vice President, General Counsel & Corporate Compliance Officer

Scott Koenig M.D., Ph.D.CEO

President, Chief Executive Officer & Director

Eric Blasius RisserCOO

Chief Operating Officer

Thomas M. Spitznagel Ph.D.

Senior Vice President of Technical Operations

Management

James KarrelsCFO

Senior Vice President, Chief Financial Officer & Corporate Secretary

Stephen L. Eck M.D., Ph.D.

Senior Vice President of Clinical Development & Chief Medical Officer

Beth Smith

Vice President, Controller & Treasurer

Ezio Bonvini M.D.

Senior Vice President of Research & Chief Scientific Officer

Jeffrey Stuart Peters J.D.

Senior Vice President, General Counsel & Corporate Compliance Officer

Scott Koenig M.D., Ph.D.CEO

President, Chief Executive Officer & Director

Eric Blasius RisserCOO

Chief Operating Officer

Thomas M. Spitznagel Ph.D.

Senior Vice President of Technical Operations

Total 8 executives

MGNX Frequently asked questions

What is MacroGenics, Inc. (MGNX) Stock Price?

Current stock price of MacroGenics, Inc. (MGNX) stock is $4.320. The stock price is +6.93% higher in the session. The intraday range can be seen from this page. Volume of MacroGenics, Inc. (MGNX) stock is 581.57K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the MacroGenics, Inc. (MGNX) stock price going up or down today?

The stock price of MacroGenics, Inc. (MGNX) can change with earnings, company news, and overall market sentiment. MacroGenics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the MacroGenics, Inc. stock expensive at its current price?

Whether MacroGenics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for MGNX on this page is -3.93. EPS on this page is -1.10. Compare those figures with peers and growth expectations before deciding if the current MacroGenics, Inc. price is justified.

How has the stock price of MacroGenics, Inc. (MGNX) performed historically?

Historical performance for MacroGenics, Inc. (MGNX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how MGNX reacted to past earnings and market events.

Should I buy MacroGenics, Inc. (MGNX) stock, at this price?

Buying MacroGenics, Inc. (MGNX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.